🎉 M&A multiples are live!
Check it out!

Ocular Therapeutix Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ocular Therapeutix and similar public comparables like Julphar, Benevolent AI, and Galapagos.

Ocular Therapeutix Overview

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.


Founded

2006

HQ

United States of America
Employees

274

Website

ocutx.com

Financials

LTM Revenue $65.8M

LTM EBITDA -$180M

EV

$887M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ocular Therapeutix Financials

Ocular Therapeutix has a last 12-month revenue of $65.8M and a last 12-month EBITDA of -$180M.

In the most recent fiscal year, Ocular Therapeutix achieved revenue of $63.7M and an EBITDA of -$176M.

Ocular Therapeutix expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ocular Therapeutix valuation multiples based on analyst estimates

Ocular Therapeutix P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $58.4M $63.7M XXX XXX XXX
Gross Profit $47.0M $53.2M XXX XXX XXX
Gross Margin 80% 83% XXX XXX XXX
EBITDA -$66.4M -$176M XXX XXX XXX
EBITDA Margin -114% -276% XXX XXX XXX
Net Profit -$71.0M -$80.7M XXX XXX XXX
Net Margin -122% -127% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ocular Therapeutix Stock Performance

As of April 15, 2025, Ocular Therapeutix's stock price is $8.

Ocular Therapeutix has current market cap of $1.2B, and EV of $887M.

See Ocular Therapeutix trading valuation data

Ocular Therapeutix Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$887M $1.2B XXX XXX XXX XXX $-1.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ocular Therapeutix Valuation Multiples

As of April 15, 2025, Ocular Therapeutix has market cap of $1.2B and EV of $887M.

Ocular Therapeutix's trades at 13.5x LTM EV/Revenue multiple, and -4.9x LTM EBITDA.

Analysts estimate Ocular Therapeutix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ocular Therapeutix and 10K+ public comps

Ocular Therapeutix Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $887M XXX XXX XXX
EV/Revenue 13.9x XXX XXX XXX
EV/EBITDA -5.0x XXX XXX XXX
P/E -6.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ocular Therapeutix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ocular Therapeutix Valuation Multiples

Ocular Therapeutix's NTM/LTM revenue growth is 11%

Ocular Therapeutix's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Ocular Therapeutix's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ocular Therapeutix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ocular Therapeutix and other 10K+ public comps

Ocular Therapeutix Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 9% XXX XXX XXX XXX
EBITDA Margin -276% XXX XXX XXX XXX
EBITDA Growth 165% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -265% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue 8% XXX XXX XXX XXX
G&A Expenses to Revenue 152% XXX XXX XXX XXX
R&D Expenses to Revenue 200% XXX XXX XXX XXX
Opex to Revenue 361% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ocular Therapeutix Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ocular Therapeutix M&A and Investment Activity

Ocular Therapeutix acquired  XXX companies to date.

Last acquisition by Ocular Therapeutix was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ocular Therapeutix acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ocular Therapeutix

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ocular Therapeutix

When was Ocular Therapeutix founded? Ocular Therapeutix was founded in 2006.
Where is Ocular Therapeutix headquartered? Ocular Therapeutix is headquartered in United States of America.
How many employees does Ocular Therapeutix have? As of today, Ocular Therapeutix has 274 employees.
Who is the CEO of Ocular Therapeutix? Ocular Therapeutix's CEO is Dr. Pravin U. Dugel, M.D..
Is Ocular Therapeutix publicy listed? Yes, Ocular Therapeutix is a public company listed on NAS.
What is the stock symbol of Ocular Therapeutix? Ocular Therapeutix trades under OCUL ticker.
When did Ocular Therapeutix go public? Ocular Therapeutix went public in 2014.
Who are competitors of Ocular Therapeutix? Similar companies to Ocular Therapeutix include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ocular Therapeutix? Ocular Therapeutix's current market cap is $1.2B
What is the current revenue of Ocular Therapeutix? Ocular Therapeutix's last 12-month revenue is $65.8M.
What is the current EBITDA of Ocular Therapeutix? Ocular Therapeutix's last 12-month EBITDA is -$180M.
What is the current EV/Revenue multiple of Ocular Therapeutix? Current revenue multiple of Ocular Therapeutix is 13.5x.
What is the current EV/EBITDA multiple of Ocular Therapeutix? Current EBITDA multiple of Ocular Therapeutix is -4.9x.
What is the current revenue growth of Ocular Therapeutix? Ocular Therapeutix revenue growth between 2023 and 2024 was 9%.
Is Ocular Therapeutix profitable? Yes, Ocular Therapeutix is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.